Drawing for BIOLINERX

USPTO serial 79377712

BIOLINERX

Reviewed by CopyMark Law Group

Reg. 7484132Status 700Registered
Filing date
Status date
Registration date
Aug 27, 2024
Examiner
LOZEAU, BRANDON THOMAS
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with BIOLINERX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey H. Handelsman

Jeffrey H. Handelsman Greenblum & Bernstein, P.L.C.1950 Roland Clarke PlaceReston, VA 20191-1411United States

Goods and services

ClassDescriptionStatusFirst use
042Pharmaceutical product development services, namely, pharmaceutical product development through the discovery of compounds that helps for the treatment of a variety of diseases and symptoms; pharmaceutical product development services for a wide variety of diseases and symptoms, namely, neuropathic pain, acute kidney injury, inflammatory bowel disease, adult diabetes, weight loss among cancer patients, bacterial infections, rheumatoid arthritis, celiac disease, psoriasis, solid cancerous tumors, myocardial infarction, schizophrenia and prostate cancer; pharmaceutical product development services of new compounds for use in medicines for oncology patients; pharmaceutical research services; research and development services in the field of biotechnologyACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 8, 2025FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Feb 15, 2025FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 15, 2025OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Feb 15, 2025FIMPFINAL DISPOSITION PROCESSED—
Jan 27, 2025OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jan 26, 2025OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Nov 29, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Aug 27, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Aug 27, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 11, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 11, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 22, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 8, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 7, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 7, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 7, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 7, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 7, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 7, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 7, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 7, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 7, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 2, 2024RFNTREFUSAL PROCESSED BY IB—
Mar 17, 2024LIMELIMITATION FROM THE IB - REQUEST EXAM REVIEW—
Mar 13, 2024RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 12, 2024RFRRREFUSAL PROCESSED BY MPU—
Feb 21, 2024RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 20, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 15, 2024DOCKASSIGNED TO EXAMINER—
Jan 28, 2024LIMGLIMITATION OF GOODS RECEIVED FROM IB—
Sep 5, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 1, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 31, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance